Neurologia
Revisão sistemática | Prevenção de polineuropatia distal periférica em pacientes com diabetes.
13 Mai, 2022 | 12:30hDemências rapidamente progressivas: etiologias, diagnóstico e tratamento.
12 Mai, 2022 | 14:38hRapidly progressive dementias — aetiologies, diagnosis and management – Nature Reviews Neurology (se o acesso a este link for pago, tente este em PMC)
Revisão | Avaliação e tratamento da função cognitiva de pacientes com câncer de próstata tratados com inibidores do receptor androgênico de segunda geração.
12 Mai, 2022 | 14:18hEstudo randomizado | Ravulizumabe, um inibidor do complemento terminal, na miastenia gravis generalizada.
10 Mai, 2022 | 14:13hTerminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis – NEJM Evidence
Comentário no Twitter
In this RCT, Ravulizumab provided rapid and efficacious treatment of adult patients with anti-AChR antibody-positive generalized myasthenia gravis (gMG), as determined by both patient- and clinician-rated outcomes, with few adverse events. https://t.co/9mlCOULiJR#NeuroTwitter pic.twitter.com/ZljrTs282f
— NEJM Evidence (@NEJMEvidence) May 3, 2022
Revisão sistemática | Cannabis e canabinoides para tratamento sintomático de pessoas com esclerose múltipla.
10 Mai, 2022 | 12:27hResumo: Cannabis and cannabinoids for people with multiple sclerosis – Cochrane Library
Comentário no Twitter
💚A UK survey found that 1 in 5 people with #MS reported they used #Cannabis to manage symptoms.
🤔 Does it work? Are there harms?
📚 Cochrane systematic review looks at 25 RCTs ➡️ https://t.co/HCt6Cx3suo#MedicalMarijuana #MultipleSclerosis pic.twitter.com/wjDTXXEciM— The Cochrane Library (@CochraneLibrary) May 5, 2022
Diretriz de consenso de especialistas HRS 2022 sobre avaliação e tratamento do risco de arritmias em doenças neuromusculares.
6 Mai, 2022 | 17:35hRevisão sistemática de estudos de acurácia diagnóstica | Tratamento de pacientes que se apresentam no departamento de emergência com dor de cabeça grave de início súbito.
6 Mai, 2022 | 17:28hDiretrizes atuais sobre tratamento de amaurose fugaz e ataques isquêmicos transitórios.
6 Mai, 2022 | 17:17hM-A | Eficácia e segurança do selumetinibe em pacientes pediátricos com neurofibromatose tipo 1.
6 Mai, 2022 | 17:12hEfficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis – Neurology (link para o resumo – $ para o texto completo)
Comentário no Twitter
A study via @GreenJournal reported that #selumetinib is a safe and effective treatment for pediatric patients with symptomatic, inoperable plexiform neurofibromas, but further studies are needed to confirm long-term outcomes. https://t.co/sRVaNFPKwV#NeuroTwitter pic.twitter.com/hYJNpN1EoU
— Neurology Today (@NeurologyToday) March 11, 2022
Perspectiva | Menos farmacoterapia é mais no delirium.
4 Mai, 2022 | 13:54hLess pharmacotherapy is more in delirium – Intensive Care Medicine (se o acesso a este link for pago, tente este)
Conteúdos relacionados:
Effectiveness of Bundle Interventions on ICU Delirium: A Meta-Analysis – Critical Care Medicine
Comentário no Twitter
⬇️ 💉Less medications (& ⬆️ awareness of behavioural interventions) is more in #delirium, common, challenging/costly (but often preventable) in #ICU. Despite lacking evidence, medications widely used.
Prevent/minimize addressing suspected contributors!
📎 https://t.co/fYWAsIcuiZ pic.twitter.com/DyC3agSP7w— Intensive Care Medicine (@yourICM) April 30, 2022